Cargando…

Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients

PURPOSE: Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) is a treatment for post-transplant lymphoproliferative disease (PTLD) following solid organ transplant (SOT) after failing rituximab, an aggressive and potentially fatal lymphoma. This study explores the humanistic and economic b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watson, Crystal, Barlev, Arie, Worrall, Jodie, Duff, Steve, Beckerman, Rachel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782278/ https://www.ncbi.nlm.nih.gov/pubmed/33489434 http://dx.doi.org/10.1080/21556660.2020.1854561

Ejemplares similares

A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen
por: Watson, Crystal, et al.
Publicado: (2022)

Qualitative Findings on the Impact of Disease in Epstein–Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Patients, as Measured by EQ-5D, SF-36, and the FACT-LYM
por: Watson, Crystal, et al.
Publicado: (2020)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy
por: Lu, Yaxiao, et al.
Publicado: (2021)

Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy
por: Fournier, Q., et al.
Publicado: (2017)

Remission of late-onset post-heart transplantation lymphoproliferative disorder following treatment with rituximab and modified mini-CHOP chemotherapy: A case report
por: HUANG, QIANG, et al.
Publicado: (2016)

CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi
por: Gopal, Satish, et al.
Publicado: (2016)

Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma
por: Choi, Eun-Ji, et al.
Publicado: (2017)

Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice
por: Bascuas, Thais, et al.
Publicado: (2018)

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy
por: Pettengell, R., et al.
Publicado: (2008)

RNA-Seq analysis of gene expression in 25 cases of canine lymphoma undergoing CHOP chemotherapy
por: Mee, Miles W., et al.
Publicado: (2022)

R-CHOP versus CHOP in HIV-associated lymphoma: a meta-analysis of prospective studies
por: Echenique, Ignacio, et al.
Publicado: (2012)

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma
por: Lisenko, K., et al.
Publicado: (2017)

Zanubrutinib in lymphoproliferative disorders: a comprehensive review
por: Muñoz, Javier, et al.
Publicado: (2022)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV(+) PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study
por: Chaganti, Sridhar, et al.
Publicado: (2023)

The lymphoma microenvironment comes of age in the R-CHOP era?
por: Cooper, Alan, et al.
Publicado: (2023)

Oral CHOP‐like chemotherapy in 60–80 years‐old patients with diffuse large B‐cell lymphoma
por: Guidez, Stephanie, et al.
Publicado: (2019)

Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy
por: Kim, Tark, et al.
Publicado: (2012)

High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas
por: Huang, Li-Wen, et al.
Publicado: (2021)

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
por: Johnson, William T., et al.
Publicado: (2023)

Results from Patient Interviews on Fatigue in Progressive Multiple Sclerosis and Evaluation of Fatigue Patient-Reported Outcome (PRO) Instruments
por: Watson, Crystal, et al.
Publicado: (2022)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen
por: Chen, Xing-Gui, et al.
Publicado: (2011)

A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma
por: Swaneveld, F. H., et al.
Publicado: (2007)

A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving Complete Remission with Rituximab-CHOP Chemotherapy
por: Kim, Kyung Min, et al.
Publicado: (2009)

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
por: Pettengell, Ruth, et al.
Publicado: (2011)

Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma
por: Park, Hyung Chul, et al.
Publicado: (2013)

Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study
por: Ji, Dongmei, et al.
Publicado: (2016)

Hormonal Changes after R-CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Prospective Study
por: Manosroi, Worapaka, et al.
Publicado: (2022)

A Dramatic Response of a Thyroid Lymphoma to R-CHOP Chemotherapy Reversing Mechanical Airway Obstruction and Respiratory Failure
por: Alnahas, Zeinab, et al.
Publicado: (2022)

RNA disruption indicates CHOP therapy efficacy in canine lymphoma
por: Parissenti, Amadeo M., et al.
Publicado: (2019)

Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021
por: Watson, Crystal, et al.
Publicado: (2023)

Lymphoma and cerebral vasculitis in association with X-linked lymphoproliferative disease
por: Zhu, Jia, et al.
Publicado: (2013)

Treatment Outcomes with CHOP Chemotherapy in Adult Patients with Hemophagocytic Lymphohistiocytosis
por: Shin, Ho-Jin, et al.
Publicado: (2008)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

Metronomic chemotherapy for indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract
por: Liu, Hailing, et al.
Publicado: (2023)

Erratum to: Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
por: Pettengell, Ruth, et al.
Publicado: (2012)

Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy
por: Kang, Hye Jin, et al.
Publicado: (2020)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2nnvd2v1mjc5mo1r79jp1dpc6a